FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:103-104 July 1, 2004 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Garg, A. PubMed Citation

To the Editor: The pathogenesis and management of lipodystrophy in patients with human immunodeficiency virus (HIV) infection are discussed in Garg's review article (March 18 issue).¹ However, the author should have noted that several lines of evidence point toward nucleoside reverse-transcriptase inhibitors in general, and the mitochondrial toxicity of stavudine in particular, as having a contributory role in this form of fat wasting. Clinical trials have demonstrated that the presence or absence of stavudine in the nucleoside reverse-transcriptase–inhibitor "backbone" of antiretroviral regimens has an influence on the risk of lipoatrophy.² Nucleoside reverse-transcriptase inhibitors may inhibit gamma-polymerase, the enzyme necessary for . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.